{"id":"arry-382-cfms-inhibitor-oral","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"cFMS is a receptor tyrosine kinase involved in the regulation of cell growth and survival. Inhibiting cFMS has been shown to have anti-tumor effects in various cancers.","oneSentence":"cFMS inhibitor","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:54:45.873Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors"}]},"trialDetails":[{"nctId":"NCT01316822","phase":"PHASE1","title":"A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers","status":"COMPLETED","sponsor":"Array Biopharma, now a wholly owned subsidiary of Pfizer","startDate":"2011-03","conditions":"Metastatic Cancer","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"ARRY-382, cFMS inhibitor; oral","genericName":"ARRY-382, cFMS inhibitor; oral","companyName":"Array Biopharma, now a wholly owned subsidiary of Pfizer","companyId":"array-biopharma-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"cFMS inhibitor Used for Solid tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}